Pharmafile Logo
Pharmafocus logo
Advanced Search

antiplatelet

Showing 3 posts of 3 posts found.

Merck’s vorapaxar fails in late-stage trial

November 15, 2011
ACS, Brilinta, Efient, Merck, Plavix, antiplatelet, vorapaxar

Merck’s novel blood thinner vorapaxar has failed to meet its primary endpoint in a late-stage study.The TRACER trial compared vorapaxar …

News
AZ's Brilinta (ticagrelor)

FDA approves AstraZeneca’s Brilinta after delay

July 21, 2011
Sales and Marketing AstraZeneca, Brilinta, Brilique, antiplatelet

The FDA has finally approved AstraZeneca’s oral blood thinner Brilinta after asking for more information on the drug last year.  …

News

AZ’s Brilique approved in Europe

December 7, 2010
Sales and Marketing AZ, AstraZeneca, Brilique, Plavix, acute coronary syndromes, antiplatelet, atherothrombotic events, ticagrelor

European regulator have approved AstraZeneca’s oral antiplatelet Brilique (ticagrelor tablets). Brilique can now be used for the prevention of atherothrombotic …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024